The Smoke and Mirrors of U.S. Drug Pricing: From $9,000 Cancer Pills to the Middlemen Starving Your Local Pharmacy

If you want to understand just how fundamentally broken the American healthcare system is, look no further than a single bottle of generic leukemia medication called imatinib (originally branded as Gleevec).

At a traditional corporate pharmacy using standard health insurance, a one-month supply of this life-saving generic drug can cost a patient close to $10,000. Yet, the active chemical ingredients inside that exact same pill only cost about $5 to $25 to mass-produce.

This staggering markup is not driven by manufacturing complexity or scientific research. It is the direct byproduct of a heavily manipulated, multi-billion-dollar middleman economy. When billionaire entrepreneur Mark Cuban launched the Mark Cuban Cost Plus Drug Company in 2022, he bypassed this entire apparatus. 

By purchasing directly from manufacturers and adding a flat, transparent 15% markup, Cuban’s platform sells the exact same cancer drug for roughly $47 a month.

How can a life-saving drug cost $9,000 through insurance, but only $47 cash? The answer lies within the hidden world of Pharmacy Benefit Managers (PBMs) and discount platforms like GoodRx.

The PBM Rebate Trap: How Middlemen Drive Up Prices

In the late 1960s, a new type of company emerged called the Pharmacy Benefit Manager (PBM). Originally, they served as simple third-party administrators hired to help insurance companies process paper prescription claims.

Over the decades, massive corporate consolidation occurred. Today, just three giant conglomerates (CVS Caremark, Express Scripts, and OptumRx) control approximately 80% of the entire U.S. prescription drug market.

Instead of negotiating to lower prices, PBMs actively drive them up using their absolute control over the formulary—the list of medications an insurance plan agrees to cover. 

To get their products placed on this approved list, drug manufacturers must pay PBMs massive, confidential kickbacks known as rebates.

This dynamic creates a highly predatory incentive structure: PBMs routinely favor high-priced, brand-name drugs over cheaper alternatives because a higher initial sticker price yields a much larger rebate check for the PBM to pocket. 

If a drug's price drops to its true competitive value, the middlemen lose their profit margins.

The GoodRx Illusion: Why Free Coupons Can Kill Small Pharmacies

Faced with astronomical insurance copays, millions of Americans have turned to digital coupon apps like GoodRx. 

While GoodRx can significantly lower out-of-pocket costs for an individual consumer at the counter, it acts as a silent executioner for independent, neighborhood pharmacies.

GoodRx is not a pharmacy; it is a digital marketing platform built directly on top of the existing PBM infrastructure. 

When a patient presents a GoodRx coupon, the transaction is processed through a PBM network. This shifts the financial burden entirely onto the pharmacy:

• Below-Cost Pricing: GoodRx coupons often slash the retail price below what an independent pharmacy paid to buy the medicine from their wholesaler.

• The PBM Transaction Fee: On top of forcing the pharmacy to sell the drug at a raw loss, the PBM charges the pharmacy a mandatory "adjudication fee" (often $3 to $6) just to process the GoodRx transaction.

• The Profit Split: The PBM pockets this transaction fee and splits a portion of it with GoodRx.

While massive corporate retail chains can absorb these losses to drive foot traffic into their stores, independent pharmacies cannot. These hidden processing fees and clawbacks routinely drive local pharmacies into financial insolvency.

Do Other Countries Rely on PBMs?

No. The complex, multi-layered PBM model is a uniquely American phenomenon.

In other developed nations, governments don't rely on private middlemen to negotiate drug prices. Instead, countries like France, Japan, and the United Kingdom utilize universal single-payer frameworks. The state health ministry negotiates directly with pharmaceutical manufacturers to set strict, uniform national price caps on medications. If a pharmaceutical company wants access to that country’s entire population, it must agree to a fair, regulated price. Because there are no private insurance networks or competing formularies, the need for a PBM middleman is entirely eliminated.

Which Country Has the Cheapest Prescription Drugs?

Global pricing audits consistently find that Turkey features the cheapest prescription drug prices among major audited nations.

According to comprehensive international cost data compiled by the RAND Corporation, the average list price for a prescription medication in the United States is nearly eight times higher than the exact same medicine sold in Turkey. Across peer nations with strong economies, countries like Japan and Australia frequently offer the lowest prices for modern brand-name medications due to aggressive national price-setting policies.

The Takeaway

The multi-thousand-dollar price tags on American pharmacy shelves are not a reflection of scarcity or chemical complexity. The United States does not have a drug manufacturing crisis; it has a middleman crisis. Until systemic policy changes break the grip of PBM rebate loops and corporate consolidation, American patients will continue paying premium prices for a game that is rigged from the start.

Valium, Sybil, Satanic Day Care Centers, Prozac, Xanax, ADHD and Gender Dysphoria. What they all have in common?

    Gender dysphoria diagnoses surged recently, with Reuters reporting 42K U.S. kids/teens diagnosed in 2021, nearly 3x 2017's number. From 2017-2021, at least 121,882 kids aged 6-17 got this diagnosis. 

    A 2016 Journal of Adolescent Health review labeled these kids "singularly vulnerable" due to high depression, self-harm, and suicide rates. The APA's DSM notes kids can't fully grasp gender identity, and most eventually accept their biological sex, ceasing to identify as the opposite.

   Aiding this increase is the Fourth Circuit Court of Appeals recently ruled that “gender dysphoria” is not categorically excluded from the ADA’s definition of “disability.” When enacted in 1990, the ADA excluded certain diagnoses, including the now-obsolete “gender identity disorders.” In Williams v. Kincaid, the court examined whether “gender dysphoria,” a more recent diagnosis, falls under this exclusion or is a distinct condition.

   The disability Law Center of Virginia argued in an amicus brief that gender dysphoria is separate from “gender identity disorders.” The court agreed, stating that gender dysphoria involves “discomfort or distress caused by a discrepancy between a person’s gender identity and their sex assigned at birth,” often treatable with medical interventions like hormonal therapy. 

  The court distinguished it from “gender identity disorders” due to its focus on clinically significant distress, not just gender identity. On June 30, 2023, the U.S. Supreme Court denied the defendant’s petition for certiorari, upholding the Fourth Circuit’s decision.

   Transgender identity is not a disability, and not all transgender individuals have or identify with a gender dysphoria diagnosis. However, per Williams v. Kincaid, those diagnosed with gender dysphoria in the Fourth Circuit—covering Maryland, North Carolina, South Carolina, Virginia, and West Virginia—are not excluded from ADA protections.

   Children may qualify for SSI benefits if medical conditions cause marked, severe functional limitations. SSA assesses cases individually, considering overall condition and impact on age-appropriate activities.

   So it seems that with any new disorders comes increase of of diagnosis. Along with increase of disability claims. This is often seen in psychiatry thru out the decades. In the 1960s Valium came out and everyone was stressed out and needed a prescription of Valium.

    8 years later Valium was the most abused medication and another disorder that comes along in psychiatry is benzo addiction and treatment of Valium withdrawal at psychiatric hospitals. 

   Sybil the book then movie comes out in the 1970s and a new star is born in psychiatric diagnosis "Multiple Personality disorder". 

   NPR reports that, after the book and film, diagnoses went from a few hundred to thousands. By the late 1980s, there were 40,000 cases diagnosed in the United States alone. Some experts argue that the popularity of "Sybil" contributed to overdiagnosis of the condition. It's also important to note that the real person behind "Sybil," Shirley Mason, later admitted that her multiple personalities were fabricated. 

      So that brings us to the 1980s and satanic cults in day care centers across America. Prozac and Xanax late 80s,  a wonder antidepressant that everyone needed to a new benzodiazipine that wasn't addictive because it's short half life.  5 years later psychiatry learns the hard way, Xanax was the most addictive and abused tranquilizer and needed hospitalization to come off of.

   ADHD, ADD, The Twinkie Defense( Yes it's a real psychiatric defense) to Video Game, Porn, Food Addiction and now the pseudoscience of Gender Affirming care that is a multi-billion dollar industry in America. Psychiatry, Surgeons, Non-Profits, Venture capitalists, Pharmaceutical companies, Cable shows(I Am Jazz) to Pro Palestinian groups jumping on the band wagon to get their share of the pie of the Islam Loving Free Palestinian Transgender community.

    Yet as I summize this will go the way the other attempts that psychiatry tried to validify a new revenue stream of diagnosis. Like Sybil who faked 16 personalities and now how over 200,000 Adolescents claiming to be something there not just seem to be learning from Sybil her/him/it self.